Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Pharmas Look To Herbal Medicines As Huge Potential (India)

This article was originally published in PharmAsia News

Executive Summary

India's $1 billion herbal medicine industry is expected to grow by as much as 15 percent a year as pharmaceutical companies see its potential. Much of the interest is in Western countries, with Indians slow to rely on the alternative drugs. Prescription herbal medicine accounts for only 30 percent of the market for Indian companies, with the other 70 percent over-the-counter products. Prescription herbal medicine generally lack clinical-trial data, with those backed by accepted research selling the best in India, which is one of the largest producers of medicinal herbs. One drug company executive said many pharmaceutical companies see herbal health care as having huge potential. (Click here for more

You may also be interested in...



CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel